

Impact of National Lung Cancer Audit

NATIONAL

How the project provides evidence of quality and outcomes of care nationally

More patients receiving early stage diagnosis
29% in 2018 versus 26% in 2015
Fewer patients being diagnosed at late stage
49% in 2018 versus 53% in 2015

Increase in 1-year survival in stage III patients
63% in 2018 versus 45% for 2015

Annual report on 2018 data, communications promoted in English and Welsh

Increase in patients with **access to specialist nursing**, 74% in 2018 versus (versus 71% for 2016)

39,754 new cases confirmed in 2018 data report, this included 2,228 cases from Wales

Data completeness improvements: e.g. disease stage is recorded in over 95% of patients (99% in Wales)

2019 [PHE 2nd atlas of variation](#) widely cites the NLCA associating the NLCA with improvements in lung cancer survival

SYSTEM

How the project supports policy development & system management

[NHS Long term plan](#) informed by NLCA data (section 3.56)

[NICE Lung Cancer quality standards](#) (4 new measures added in 2019 with NLCA on the consultation panel) and NICE 2019 clinical guideline underpinned by NLCA data

Public Health England developed a [lung cancer specific](#) atlas of variation using NLCA data

139 GIRFT site-visits underpinned by NLCA data and NLCA input into **GIRFT National report**

NHS England Specialist Commissioning Group considering specialist service commissioning for lung cancer, prompted by organisational audit *"Only 5% of MDTs have adequate staffing"*

CQC and Welsh government notified of NLCA identified outliers

[2019 NICE Impact Report on Lung Cancer](#) widely cites the NLCA

International reach enquiries received from Australia, wanting to set up similar audit

LOCAL

How the project stimulates quality improvement

100% participation in the 15th annual report

Trust's benchmarked against **six outlier measures** including two new measures for 20(18): assessment by a specialist nurse and curative intent treatment in patients with stage I-II NSCLC and PS 0-2 NSCLC

Outlier support (one to one engagement and signposting)

Outlier process in collaboration with Trusts including 22 English and 2 Welsh negative 'alarm-level' outliers

Increasing [evidence from local services](#) of improvements following on from outliers status and NLCA results

[Quality improvement toolkit](#)

89 English and 6 Welsh organisations identified and congratulated as **positive outliers**

Over **1300** clinicians and stakeholders signed up to monthly NLCA newsletter

PUBLIC

How the project is used by the public and the demand for it

671 downloads of the latest NLCA reports available in the public domain and over **5000** webpage visits during 2020

4 conference abstracts or presentations since March 2020, including presentation at [Medicine 2021](#)

12 academic journal and news articles cite NLCA data since March 2020

Video ["Understanding the National Lung Cancer Audit"](#) published October 2020, 1259 impressions on Twitter and 216 views on YouTube (as of February 2021)

Twitter followers have almost doubled from 568 in August 2020 to **1010** in February 2021. With over **32K** twitter impressions, **664** engagements, **124** likes

[NLCA patient and carer booklet](#) produced annually in collaboration with RCLCF

[BMJ](#) cites the NLCA as an example of an audit that has been successful in driving improvement and reducing variations in care

Glossary

BMJ British Medical Journal

CQC Care quality commission

GIRFT Getting it right first time

MDT multidisciplinary team

NICE National institute for health and care excellence

RCLCF Roy castle Lung Cancer Foundation

General notes

The year quoted for data relates to the diagnosis year not the report publication year.

NICE 2019 clinical guideline. Most of the assumptions use NLCA data to drive recommendations regarding prevalence and cost effectiveness.

COVID-19 has affected some areas of impact for the NLCA including delays to the outlier process and access to data.